DocuSign Envelope ID: 768849B1-3CF8-41F2-9B73-88A4552CBB29

Nurofen Limited

Directors' Report and Unaudited Financial Statements

For the year ended 31 December 2020

Registered number: 00905237

THURSDAY
AAD4HFYH
A10 16/09/2021 #130
COMPANIES HOUSE

DocuSign Envelope ID: 768849B1-3CF8-41F2-9B73-88A4552CBB29

Contents

	Page
Directors' Report	2
Balance Sheet	3
Statement of Changes in Equity	4
Notes to the Financial Statements	5

DocuSign Envelope ID: 768849B1-3CF8-41F2-9B73-88A4552CBB29

Nurofen Limited

Directors' Report for the year ended 31 December 2020

The Directors of Nurofen Limited ("the Company") present their report together with the unaudited Financial Statements for the year ended 31 December 2020.

Results

The Company did not trade during the current or preceding year and accordingly no Statement of Comprehensive Income has been prepared. The Company has not received any income or incurred any expense or recognised any other recognised gains or losses during the current or preceding year.

Directors

The Directors of the Company who held office during the year and up to the date of signing of the Financial Statements, unless otherwise stated, were as follows:

Timothy John Martel (appointed 8 June 2020)
Richard Mark Greensmith
Jonathan Timmis (resigned 8 June 2020)

Dividends

The Directors paid £nil dividends during the year (2019: £nil).

In preparing this report, the Directors have taken advantage of the small companies' exemptions provided by section 415A of the Companies Act 2006.

Approved by the Board and signed on its behalf by:

DocuSigned by:
Tim Martel
3EF9BAFB89F04F6...

Timothy John Martel
Director

Date: 14 September 2021

DocuSign Envelope ID: 768849B1-3CF8-41F2-9B73-88A4552CBB29

Balance Sheet
at 31 December 2020

	Note	**31 December 2020** £	**31 December 2019** £
Current Assets			
Debtors due within one year	2	399,865	399,865
Net Assets		**399,865**	**399,865**
Capital and Reserves			
Share Capital	3	100	100
Retained earnings		399,765	399,765
Total Equity		**399,865**	**399,865**

For the year ended 31 December 2020 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 (the "Act") relating to dormant companies.

The members have not required the Company to obtain an audit of its Financial Statements for the year in question in accordance with section 476 of the Act.

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of Financial Statements.

These Financial Statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

These Financial Statements were approved by the Board of Directors and authorised for issue on 14 September 2021.

DocuSigned by:
Tim Martel
3EF9BAFB89F04F6...

Timothy John Martel
Director

DocuSign Envelope ID: 768849B1-3CF8-41F2-9B73-88A4552CBB29

Statement of Changes in Equity
at 31 December 2020

	Share capital £	Retained earnings £	Total £
At 31 December 2018	100	399,765	399,865
Profit for the year	-	-	-
At 31 December 2019	**100**	**399,765**	**399,865**
Profit for the year	-	-	-
At 31 December 2020	**100**	**399,765**	**399,865**

DocuSign Envelope ID: 768849B1-3CF8-41F2-9B73-88A4552CBB29

Notes to the Financial Statements

1 Accounting policies

The Financial Statements have been prepared on a going concern basis, under the historical cost convention and in compliance with United Kingdom Accounting Standards, including Financial Reporting Standard 102, "The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102") and the Companies Act 2006.

The Company is a member of the Reckitt Group of companies and a wholly-owned subsidiary of Reckitt Benckiser Group plc (the "Group"), a company incorporated in England and Wales, which has prepared publicly available consolidated accounts which include the Company.

a) General Information

Nurofen Limited is a private limited company incorporated in England and Wales under the Companies Act 1948, and is subject to the requirements of the Companies Act 2006. The address of the registered office is 103-105 Bath Road, Slough, Berkshire, SL1 3UH. The Company did not trade during the year.

b) Financial Reporting Standard 102 – Reduced Disclosure Exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these Financial Statements, as permitted by FRS 102 for qualifying entities:

- The requirements of section 3 Financial Statement Presentation paragraph 3.17(d) and section 7 Statement of Cash Flows not to prepare a statement of cash flows;
- The requirements of section 4 Statement of Financial Position paragraph 4.12(a)(iv) not to prepare a reconciliation of the numbers of shares outstanding at the beginning and end of the year; and
- The requirements of section 33 Related Party Disclosures paragraph 33.7 not to disclose key management personnel compensation in total.

2 Debtors due within one year

	2020 £	2019 £
Amounts owed by Group undertakings	399,865	399,865

The amounts owed by Group undertakings are unsecured, repayable on demand and non-interest bearing.

3 Share capital

	2020 £	2019 £
Allotted, and fully paid		
100 Ordinary shares of £1 each	100	100

4 Ultimate controlling party

The Company is a subsidiary undertaking of RB Holdings (Nottingham) Limited, a company registered in England and Wales. Reckitt Benckiser Group plc, a company incorporated in England and Wales, is the ultimate parent company and the Directors regard it as the ultimate controlling party.

Reckitt Benckiser Group plc is the parent company of the largest and smallest group of which the Company is a member and for which group accounts are drawn up. Copies of the accounts are available from Reckitt Benckiser Group plc, 103-105 Bath Road, Slough, Berkshire, SL1 3UH or at http://www.reckitt.com.